Paul Scorer - Concepedia

Author

Paul Scorer

AstraZeneca (United Kingdom)

Also Known As

P Scorer, P. Scorer, Paul M Scorer, Paul Scorer

Publications

730

Citations

H-Index

Concepts

All Affiliations

AstraZeneca (United Kingdom)Queen Elizabeth Hospital

About

Paul Scorer is an author at AstraZeneca (United Kingdom) specializing in medicine, pathology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	200
2	Health Sciences	1	1	19
3	Natural Sciences	1	1	11
4	Biochemistry	1	1	11
5	Cell Biology	1	1	76

Paul Scorer

Publications

689

Citations

H-Index

Page 1

	Year	Citations
Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non–Small Cell Lung Cancer M. Ratcliffe, Alan Sharpe, Anita Midha, Clinical Cancer Research	2017	303
Phospho‐STAT5 and phospho‐Akt expression in chronic myeloproliferative neoplasms Lizz Grimwade, Lisa Happerfield, Colin Tristram, British Journal of Haematology ImmunologyPathologyCell DeathBone Marrow TrephinesTumor Biology	2009	76
Prevalence of HER2 low in breast cancer subtypes using the VENTANA anti-HER2/neu (4B5) assay. Marietta Scott, Michel E. Vandenberghe, Paul Scorer, Journal of Clinical Oncology Breast OncologyImmunologyPathologyImmunotherapeuticsImmunotherapy	2021	49
Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma M Zając, Marietta Scott, M. Ratcliffe, Diagnostic Pathology	2019	47
Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay Paul Scorer, Marietta Scott, Nicola Lawson, Diagnostic Pathology	2018	36
The hormonal receptor status of uterine carcinosarcomas (mixed müllerian tumours): an immunohistochemical study. Anca C. Ansink, Paul Cross, Paul Scorer, Journal of Clinical Pathology	1997	32
Comparison of patient populations identified by different PD-L1 assays in in triple-negative breast cancer (TNBC) Marietta Scott, Paul Scorer, Craig Barker, Annals of Oncology	2019	32
Plasma-based tumor mutational burden (bTMB) as predictor for survival in phase III EAGLE study: Durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) after platinum failure. Weimin Li, Sophie Wildsmith, Jiabu Ye, Journal of Clinical Oncology ImmunologyR/m HnsccPathologyRecurrent/metastatic HeadImmunotherapy	2020	27
Assessment of PD-L1 mRNA and protein expression in non-small cell lung cancer, head and neck squamous cell carcinoma and urothelial carcinoma tissue specimens using RNAScope and immunohistochemistry David Jonathan Duncan, Marietta Scott, Paul Scorer, PLoS ONE	2019	24
Abstract LB-094: A comparative study of PD-L1 diagnostic assays and the classification of patients as PD-L1 positive and PD-L1 negative M. Ratcliffe, Alan Sharpe, Anita Midha, Cancer Research DiagnosisPathologyAbstract Lb-094Translational MedicinePd-l1 Assessment	2016	19

Page 1